Article
Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma.
Frontiers in immunology - 1 Jan 2024
Wang Zeping, Zou Xiaojing, Wang Haiyan, Hao Zhihui, Li Gebin, Wang Shuaiyu
Abstract excerpt
Programmed cell death receptor 1 (PD-1), when bound to the ligand programmed death-ligand 1 (PD-L1), can suppress cellular immunity and play a critical role in the initiation and development of cancer. Immune drugs targeting these two sites have been developed for different cancers, including malignant melanoma. The accompanying diagnostic method has been approved by the FDA to guide patient medication. However,...
Topics
- Humans
- Melanoma
- Immune Checkpoint Inhibitors
- Biomarkers, Tumor
- B7-H1 Antigen
- Programmed Cell Death 1 Receptor
- Tumor Microenvironment
- Mutation
- Skin Neoplasms